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SUMMARY
Objective: Platinum-based doublet chemotherapy is considered the standard of care for 
advanced non-small cell lung cancer (NSCLC). However, prognosis after recurrent or 
progressive disease following first-line chemotherapy is usually poor. Maintenance che-
motherapy, second line treatment and even third line chemotherapy are available for pa-
tients with advanced NSCLC. Unfortunately, few patients are candidates for chemother-
apy beyond first line. The present study evaluated characteristics of patients with NSCLC 
and outcomes of the treatment of their metastatic disease, with emphasis on second and 
third-line chemotherapy. Methods: This was a retrospective observational study of 2,673 
patients with metastatic, stage IV, non-small cell lung cancer admitted for treatment 
in two São Paulo institutions. First-line chemotherapy was defined as the first chemo-
therapeutic approach administered to the patient. Second and third-line chemotherapy 
were defined as the systemic treatment administered after discontinuing first-line che-
motherapy, either for intolerance or for progressive or recurrent disease. Results: Most 
patients (57.9%) received first-line chemotherapy, and approximately 23.4% received 
second-line and 8% third-line regimens. Only 2.5% received fourth-line chemotherapy. 
Median overall survival (OS) was 8 months (95% CI: 8-9 months). At univariate analy-
ses, gender (p < 0.05), histology, first-line chemotherapy, objective response to first-line 
chemotherapy and second-line chemotherapy (p < 0.01) were prognostic factors related 
to overall survival. At multivariate analysis, only performance status (p = 0.04), receiv-
ing any second-line chemotherapy (p < 0.01) and response to first-line chemotherapy 
(p < 0.01) were independent predictors of overall survival. Conclusion: Second-line che-
motherapy is a therapeutic strategy that should be considered for a selected group of pa-
tients. Performance status and response to first-line chemotherapy could be determinant 
characteristics to select patients who might be treated beyond first-line chemotherapy. 
Keywords: Carcinoma, non-small-cell lung; neoplasm metastasis; antineoplastic com-
bined chemotherapy protocols; drug therapy; lung neoplasms.
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INTRODUCTION
Lung cancer is one of the most common cancers around 
the world. In 2008, lung cancer was responsible for 13% 
(1.6 million) of the total cancer cases and 18% (1.4 million) 
of the cancer deaths1. In USA, lung cancer remains the 
leading cause of cancer-related mortality, with estimated 
222,520 new cases and 157,300 deaths anticipated in 20102. 
In Brazil almost 30.000 new cases were expected to be di-
agnosed in 20103. Non-small cell lung cancer (NSCLC) ac-
counts for approximately 80% of all cases1. Unfortunately 
the majority of cases are detected in advanced stage4. This 
is one of the reasons that explain the poor prognosis as-
sociated with NSCLC, where nearly 15% of the patients are 
expected to survive beyond five years from the diagnosis5-7.  
Among patients with metastatic disease the prognosis is 
dismal. In spite of advances in systemic therapies, the me-
dian survival time remains around 12 months7-9. Nowadays, 
platinum-based doublet chemotherapy is considered the 
standard of care for advanced NSCLC. Results of systemic 
treatment have shown increasing overall survival as well as 
better quality of life. However, even with recent advances, 
most patients present with relapsing or progressive disease 
after first line chemotherapy. Prognosis after recurrent or 
progressive disease following first-line chemotherapy is 
usually poor. Patients who have relapsed after first line che-
motherapy and did not receive additional oncologic treat-
ment have a short overall survival, with a median around 
three months10. New drugs, such as pemetrexede, docetaxel 
and molecular targets agents have been recommended as 
valid options for second line chemotherapy, with objec-
tive response rates around 10%, and significant increase in 
overall survival, compared to best supportive care11. Nowa-
days, second line chemotherapy is considered standard 
of care in the treatment of advanced NSCLC12. The aims 
of second line chemotherapy are palliation of symptoms, 
improvement in quality of life, and increased survival. Al-
though many patients, in this clinical situation, have de-
teriorated performance status, studies have shown that up 
to 40% would be candidates to receive second-line chemo-
therapy12-14. The development of new regimens resulted in 
a significant increase in the total time spent by patients 
receiving chemotherapy. Maintenance chemotherapy, sec-
ond line treatment and even third line chemotherapy are 
available for patients with advanced NSCLC. Due to poor 
prognosis, physicians should select patients who are ad-
equate candidates to these prolonged treatments, mainly 
in countries with limited economical resources. Murillo et 
al.15 studied the characteristics of chemotherapy given near 
the end of life to advanced NSCLC patients in a community 
setting. The authors found that 56% received second line 
treatment, 26% received third line chemotherapy, 10% re-
ceived fourth line and 5% received fifth line chemotherapy 
or greater. The most interesting finding of this study is that 
almost 50% of the patients received chemotherapy in the 
last month of life, and 20% received systemic treatment in 
the last two weeks of the life. This can be explained by the 
increase demand of patients and their relatives to receive 
treatment, because they do not accept the inevitability of 
progressive disease and death. Moreover probably physi-
cians tend to offer chemotherapy to patients that will not 
have real advantages receiving this treatment, because they 
are unable to predict life expectancy. Recognition of prog-
nostic factors in patients with advanced NSCLC candidates 
to receive chemotherapy, mainly second and third lines 
treatment, is fundamental to avoid futility of therapies. 
The present study evaluateed patient characteristics of pa-
tients with NSCLC, and outcomes of the treatment of their 
metastatic disease, with emphasis on second and third-line 
chemotherapy.
METHODS 
This was a retrospective observational study of patients 
with metastatic, stage IV, non-small cell lung cancer  admit-
ted for treatment in two institutions in São Paulo, Brazil, 
dedicated to the treatment and research of cancer: Instituto 
Arnaldo Vieira de Carvalho (IAVC) and Hospital AC Ca-
margo (HACC). The study was approved by the Research 
Ethical Committee. Clinical data were reviewed from the 
records of all adult patients from 1990 to 2008. The follow-
ing inclusion criteria were considered: cytological or his-
tological diagnosis of non-small cell lung cancer; stage IV; 
and patients admitted for cancer management according to 
clinical practice guidelines of each institution. According to 
these inclusion criteria, 2,673 patients were considered for 
the present study. The following clinical data were obtained 
by reviewing individual records, registered in a consecu-
tive database: age, gender, performance status, histological 
type, chemotherapy regimens and status at last follow-up. 
Performance status was determined by Karnofsky index, ac-
cording to clinical data available in the records. Classifica-
tion of clinical staging was obtained from the records, based 
on clinical notes or reports of imaging exams (chest, upper 
abdomen CT and brain CT or MRI, and bone scan). First-
line chemotherapy was defined as the first chemotherapeu-
tic approach administered to the patient. Second and third-
line chemotherapy were defined as the systemic treatment 
administered after discontinuing first-line chemotherapy, 
either for intolerance or for progressive or recurrent disease. 
Status of last follow-up was classified as alive without dis-
ease, alive with disease, dead from cancer, dead from other 
causes, and as lost to follow-up patients who did not return 
to institution for a period exceeding twice the interval sug-
gested by the assistant physician. 
STATISTICAL ANALYSIS
The method of Kaplan-Meier was used to determine actu-
arial survival. Differences in survival were determined by 
Breslow and log rank analyses. Overall survival time was 
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defined as the interval between initial diagnosis of NSCLC 
at each center and the date of last consultation or until death. 
All statistical analyses were performed with SPSS 10.0 soft-
ware. The value of p < 0.05 was defined as significant. 
RESULTS
From 1990 to 2008, 2,673 patients with metastatic stage 
IV NSCLC had been admitted to either institution 
(IAVC: 1887, HACC:  786).  The median age of the patients 
on admission was 63 (range 24-89; mean 62.1 ± 2.5). Most 
patients (1855 – 69.4%) were male. Performance status (KPS) 
on admission was: < 70 (20.4%), 70 (28.6%), 80 (34.5%), 90 
(8.3%), 100 (1.9%), unknown (6.3%). Adenocarcinoma was 
the leading histologic subtype accounting for 32.9%, fol-
lowed by squamous-cell carcinoma (30.5%), large-cell un-
differentiated carcinoma (26.6%), and unspecified NSCLC 
(10%). Median follow-up was 9.14 months (range 0-108 
months). At the end of our study period, 69.7%, of all pa-
tients were dead, while 29.6% were still alive, and 0.7% had 
no registered information on current status. Most patients 
(57.9%) received first-line chemotherapy, and approximate-
ly 23.4% received second-line and 8% third-line regimens. 
Only 2.5% received fourth-line chemotherapy. Of the evalu-
able patients that were submitted to first-line chemotherapy, 
approximately 61.1% received a platinum-based regimen 
(cisplatin or carboplatin) and 38.9% a non-platinum-based 
therapy. Median number of cycles per patient was four 
(range 1-9). On the other hand, when second-line chemo-
therapy was administered, approximately 4.9% patients re-
ceived a platinum-based regimen (cisplatin or carboplatin) 
and over 95% a non-platinum regimen. The median num-
ber of administered cycles per patient was three (range 1-8). 
Based on the heterogeneity of the drugs used in this clinical 
setting, detailed data on toxicity were not evaluated in this 
study. Information about response rates to chemotherapy 
was determined from the records. The response rate to che-
motherapy according to the line of treatment was assessed. 
Considering all patients submitted to first line of treatment, 
79.3% had evaluable information in the records, 1.7% of 
the evaluable patients had complete response to treatment 
and 37% partial response, 11.3% had stable disease and 50% 
progressive disease. From all patients submitted to second 
line treatment, 81.6% had evaluable information in the re-
cords, 0.4% of those had complete response and 10% partial 
response to treatment, 19.6% had stable disease and 70% 
progressive disease. Considering all patients that received 
third line chemotherapy, 83.6% had evaluable information 
in the records, where no patient presented with document-
ed complete response, while 7% had partial response, 22.4% 
stable disease, and 70.6% progressive disease. 
Median overall survival (OS) was 8 months (95% CI: 
8-9 months). As most chemotherapy in second and third 
lines was administered after the year 2003, we com-
pared overall survival rates in two groups of patients: 
Those admitted until December 2003 (n  =  1,308), and 
all patients admitted after January 2004 (n  =  1,365). 
There was no statistically significant difference in overall 
survival between the two groups of patients (median sur-
vival: 7.9 months and 8.8 months, respectively, p = 0.088).
Univariate analyses of prognostic factors related to 
overall survival are shown in Table  1. At multivariate 
analysis, only performance status (p = 0.04), receiving any 
second-line chemotherapy (p < 0.01) and response to first-
line chemotherapy (p < 0.01) were independent predictors 
Variable
Median 
survival 
(months)
p  
(log-rank)
p  
(Breslow)
Hospital      
IAVC 8 0.06 0.06
HACC 9    
Gender      
Male 8 0.04 0.03
Female 9    
Age      
< 50 years 9 0.13 0.15
50 to 60 years 9    
60 to 70 years 8    
70 to 80 years 8    
> 81 years 6    
Performance status (KPS)      
60 8 0.02 0.30
70 8    
80 9    
90 to 100 8    
Histology      
Squamous cell 8 < 0.01 < 0.01
Adenocarcinoma 8    
Large cell carcinoma 5    
First-line chemotherapy      
Any chemotherapy 11 < 0.01 < 0.01
Best supportive care 4    
Objective response to 
ﬁrst-line chemotherapy     
     
Partial response 17 < 0.01 < 0.01
Stable disease 8    
Progressive disease 3    
Second-line chemotherapy      
Any chemotherapy 17 < 0.01 < 0.01
None 6    
Second-line chemotherapy      
Any chemotherapy 18 < 0.01 < 0.01
None 6    
Table 1 – Univariate analysis of overall survival (since 
admission) according patients characteristics
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of overall survival. When all NSCLC patients who received 
second and/or third-line chemotherapy were considered 
as a separate group (Figures 1 and 2), overall survival was 
significantly affected by age (p  =  0.021), where patients 
< 70 years old had a median survival of 19.7 months (range 
16-22), compared to 11.3 months (range 8-13.7), and by ob-
jective response to first line chemotherapy (p = 0.013). Pa-
tients that achieved partial response following first-line che-
motherapy presented with median survival of 19.4 months 
(range 15-24) after second and/or third-line chemotherapy, 
compared to 8.8 months (range 6-10) for patients with no 
objective response , or with progressive disease.
study came from two different Brazilian centers special-
ized in cancer treatment, and probably do not reflect the 
reality of community approaches in Brazil. Distribution 
according to gender, age, Karnofsky performance status 
and histologic type are similar to other studies that includ-
ed patients with advanced NSCLC16,17. In the last two de-
cades, chemotherapy has been established as the standard 
treatment for advanced NSCLC, in spite of its incurability 
systemic treatment improve overall survival and quality 
of life5,6,9,13. Since 1990, the availability of third generation 
drugs (gencitabine, vinorelbine, paclitaxel, docetaxel and 
irinotecan) as a CDDP-doublet have improved the results 
of treatment for advanced NSCLC, as shown by Di Maio 
et al.18 in a recently published meta-analysis. More recently 
new options as pemetrexed and molecular-target therapies 
(bevacizumab, cetuximab, thyrosine-kinase inhibitors) 
have been added to the therapeutic armamentarium to 
improve results of treatment for advanced NSCLC19,20. As 
a consequence of the development of multiple new agents 
with tolerable side effects, the length of chemotherapy for 
patients with advanced NSCLC has been increasing, with 
patients receiving chemotherapy beyond first-line drugs, 
and even maintenance treatment after initial response. The 
optimal combination of chemotherapy with target agents, 
second and third-lines chemotherapy, maintenance treat-
ments and the efficacy of new agents remains a challenge. 
Various characteristics have been used to customize the 
systemic treatment, such as performance status, histologic 
subtype, molecular markers and others. However the prog-
nosis remains poor, and one should be able to customize 
the treatment, selecting patients to different systemic ap-
proaches. The efficacy of new chemotherapeutic regimens 
should be assessed by several clinical endpoints, but over-
all survival remains as the most important in patients with 
advanced NSCLC. An increasing number of patients 
with advanced NSCLC remains in a good performance 
status after progressing with first line chemotherapy, and 
should be considered to additional treatments. In the pres-
ent study we included patients with advanced NSCLC and 
58% of them received first line treatment. Almost 24% of 
our patients received second-line treatment, 8% received 
third-line and 2.5% received fourth-line of treatment, and 
this represents a significant number of patients, consider-
ing that our series included patients since 1990, and sec-
ond line chemotherapy has became standard treatment 
since 2004. Murillo et al.15 reported different results in a 
series of patients with advanced NSCLC, 56% received 
second-line chemotherapy, 26% of patients received third-
line, fourth-line chemotherapy was administered to 10% 
of the patients, and 5% received fifth-line or greater. These 
results were observed in a community oncology setting in 
the USA, but different from the present study, the authors 
included patients from 2000 to 2003, which could explain 
higher rates of chemotherapy beyond first-line treat-
Figure 1 – Estimated overall survival (since admission) of 
patients that received second-line chemotherapy.
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Figure 2 – Estimated overall survival (since admission) of 
patients that received third-line chemotherapy.
DISCUSSION
The present observational study evaluated survival in pa-
tients with advanced NSCLC, related to systemic treat-
ment. This is the largest series of patients with advanced 
NSCLC studied in our country. Patients included in the 
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ment. Based on previous studies21-24, FDA approved only 
docetaxel, pemetrexed and erlotinib as options for sec-
ond line treatment. However different studies have been 
published with different regimens of second-line chemo-
therapy, including iriontecan, mytomicin, gencitabine, 
and even CDDP or carboplatin and other drugs25,26. In the 
present study, we could not analyze the regimens used as 
second-line treatment due to great heterogeneity of agents. 
This result is in agreement with our previous study that 
showed significant heterogeneity of regimens used in the 
treatment of patients with advanced NSCLC in Brazil27. 
The development of new options to treat patients with ad-
vanced NSCLC lead to an increase in the length of treat-
ment, but the prognosis remains poor, with only few pa-
tients surviving more than 12 months. However a select 
group of patients could be eligible to receive prolonged 
treatment with benefits in terms of survival and palliative 
care. Identifying prognostic factors is of enormous impor-
tance in order to select candidates to prolonged treatment, 
and avoid futile chemotherapy for poor prognosis patients 
that will not respond to treatment. Recently, different stud-
ies have been shown that wrong selection of patients lead 
to chemotherapy administered near the end of life, with-
out benefits and probably these treatments have worsened 
quality of life near the end26. Earle et al.28 in 2004 described 
results of a Medicare/Surveillance, Epidemiology, and End 
Results (SEER) database of more than 8,000 chemotherapy 
treated patients from 1993 to 1996 (53% of lung cancer). 
The authors observed that 16% of patients received che-
motherapy within two weeks before death. More recently, 
Di Maio et al.29, reported results of a series of 417 patients 
with advanced NSCLC treated in community setting. The 
results disclosed that 43% and 20% of the patients received 
chemotherapy within two weeks and one month before 
death, respectively. In the present study, we did not ana-
lyze the time of chemotherapy before death, but we have 
identified prognostic factors in these patients, that could 
help select patients to receive chemotherapy, even beyond 
first-line treatment. Our prognostic analysis disclosed 
that among 2,673 included patients, female gender, higher 
performance status, histology non-large-cell carcinoma, 
receive any chemotherapy, objective response to first-line 
chemotherapy, and receive second-line chemotherapy 
were determinants of better overall survival. However, at 
multivariate analysis only performance status, second-line 
chemotherapy and objective response to first-line che-
motherapy were independent determinants of prognosis. 
Moreover, analysis of patients who received second and/
or third-line chemotherapy disclosed that age less than 70 
years, and objective response after first-line chemotherapy 
were determinant of better overall survival. Di Maio et al.18 
analyzed data from nine randomized trials that included 
patients who received second-line chemotherapy. The au-
thors observed that overall survival was adversely influ-
enced by male gender, poor performance status, histology 
adenocarcinoma, patients that received platinum, and not 
obtaining objective response to first-line treatment2. Based 
in their results, a score system was proposed with the aim 
of identify patients who will obtain better outcomes after 
second-line chemotherapy. Other prognostic factors have 
been studied for advanced NSCLC patients, such as mo-
lecular markers, that might be important even for select 
chemotherapeutic agents30-32. In our study, we consider 
only the importance of characteristics that can be evalu-
ated in patients in a community clinical practice. Better 
overall survival for patients that received second-line che-
motherapy suggests that this therapeutic strategy should 
be considered for a selected group of patients. Based on 
the present results, performance status and response to 
first-line chemotherapy could be determinant character-
istics to select patients who might be treated beyond first-
line chemotherapy. Proper patient selection could increase 
the range of benefits of second/third line chemotherapy, 
and avoid futile and costly systemic treatments. Further 
studies should include also the impact of therapies beyond 
first-line on quality of life of these patients, treated rou-
tinely off protocol. 
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